Trinity Biotech (TRIB) Operating Leases (2019 - 2025)

Trinity Biotech's Operating Leases history runs 7 years deep, the most recent figure standing at $10.6 million for Q2 2025.

• In Q2 2025, Operating Leases rose 3.48% year-over-year to $10.6 million; the TTM figure through Jun 2025 stood at $10.6 million (up 3.48% YoY), while the FY2024 annual figure was $10.5 million, down 3.63% from the prior year.
• Operating Leases came in at $10.6 million for Q2 2025 at Trinity Biotech, up from $10.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $13.9 million in Q4 2021 to a low of $9.7 million in Q3 2024.
• A 5-year average of $11.3 million and a median of $10.9 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases slipped 16.42% in 2021 and gained 3.48% in 2025, its largest moves.
• Trinity Biotech's Operating Leases stood at $13.9 million in 2021, then slipped by 11.53% to $12.3 million in 2022, then slipped by 11.37% to $10.9 million in 2023, then retreated by 3.63% to $10.5 million in 2024, then gained by 0.73% to $10.6 million in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $10.6 million, $10.5 million, and $9.7 million for Q2 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison